Modulation of T cell responses by IL-2 and IL-2 complexes

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 54-57

  Boyman, Onur ^a   Kolios, Antonios G A ^a   Raeber, Miro E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD122; CD25; CD4+ T cell; CD8+ T cell; IL 2; NK cell

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 COMPLEX; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE COUNT; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; ANTIGEN ANTIBODY COMPLEX; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; THERAPEUTIC USE;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; KILLER CELLS, NATURAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84953344857     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. ROCHMAN Y, SPOLSKI R, LEONARD WJ: New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9: 480-490.
2. MALEK TR, CASTRO I: Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33: 153-65.
3. BOYMAN O, SPRENT J: The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12: 180-90.
4. LIAO W, LIN JX, LEONARD WJ: Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38: 13-25.
5. MINAMI Y, KONO T, MIYAZAKI T, TANIGUCHI T: The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245-68.
6. WALDMANN TA: The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989; 58: 875-911.
7. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
8. ROEDIGER B, KYLE R, YIP KH et al.: Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 2013; 14: 564-73.
9. YU A, ZHU L, ALTMAN NH, MALEK TR: A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009; 30: 204-17.
10. KLATZMANN D, ABBAS AK: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15: 283-94.
11. BOYMAN O, KRIEG C, HOMANN D, SPRENT J: Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci 2012; 69: 1597-608.
12. BOYMAN O, KOVAR M, RUBINSTEIN MP, SURH CD, SPRENT J: Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311: 1924-7.
13. WEBSTER KE, WALTERS S, KOHLER RE et al.: In vivo expansion of T eg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206: 751-60.
14. LETOURNEAU S, VAN LEEUWEN EM, KRIEG C et al.: IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor {alpha} subunit CD25. Proc Natl Acad Sci USA 2010; 107: 2171-6.
15. KRIEG C, LETOURNEAU S, PANTALEO G, BOYMAN O: Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010; 107: 11906-11.
16. LEVIN AM, BATES DL, RING AM et al.: Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012; 484: 529-33.
17. PICCIRILLO CA, SHEVACH EM: Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16: 81-8.
18. THORNTON AM, DONOVAN EE, PICCIRILLO CA, SHEVACH EM: Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172: 6519-23.
19. SETOGUCHI R, HORI S, TAKAHASHI T, SAKAGUCHI S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005 201: 723-35.
20. SAKAGUCHI S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
21. FONTENOT JD, RASMUSSEN JP, GAVIN MA, RUDENSKY AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-51.
22. LETOURNEAU S, KRIEG C, PANTALEO G, BOYMAN O: IL-2-and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123: 758-62.
23. BARRON L, DOOMS H, HOYER KK et al.: Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 2010; 185: 6426-30.
24. RUBTSOV YP, NIEC RE, JOSEFOWICZ S et al.: Stability of the regulatory T cell lineage in vivo. Science 2010; 329: 1667-71.
25. SCHALLENBERG S, TSAI PY, RIEWALDT J, KRETSCHMER K: Identification of an immediate Foxp3(-) precursor to Foxp3(+) regulatory T cells in peripheral lymphoid organs of nonmanipulated mice. J Exp Med 2010; 207: 1393-407.
26. CHEN Q, KIM YC, LAURENCE A, PUNKOSDY GA, SHEVACH EM: IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol 2011; 186: 6329-37.
27. KORETH J, MATSUOKA K, KIM HT et al.: Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-66.
28. MATSUOKA K, KORETH J, KIM HT et al.: Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5: 179ra143.
29. SAADOUN D, ROSENZWAJG M, JOLY F et al.: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365: 2067-77.
30. WILSON MS, PESCE JT, RAMALINGAM TR, THOMPSON RW, CHEEVER A, WYNN TA: Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol 2008; 181: 6942-54.
31. TANG Q, ADAMS JY, PENARANDA C et al.: Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-97.
32. LIU R, ZHOU Q, LA CAVA A, CAMPAGNOLO DI, VAN KAER L, SHI FD: Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010; 40: 1577-89.
33. LEE SY, CHO ML, OH HJ et al.: Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunology 2012; 137: 305-16.
34. BOYMAN O, SURH CD, SPRENT J: Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006; 6: 1323-31.
35. SMITH FO, DOWNEY SG, KLAPPER JA et al.: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14: 5610-8.
36. KLAPPER JA, DOWNEY SG, SMITH FO et al.: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113: 293-301.
37. KAUFMAN HL, KIRKWOOD JM, HODI FS et al.: The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10: 588-98.
38. ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16.
39. EPSTEIN AL, MIZOKAMI MM, LI J, HU P, KHAWLI LA: Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003; 95: 741-9.
40. ANTONY PA, RESTIFO NP: CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005; 28: 120-8.
41. ROSALIA RA, ARENAS-RMIREZ N, BOU-CHAUD G, RAEBER ME, BOYMAN O: Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr Opin Chem Biol 2014; 23: 39-46.
42. KLEIN B, BRAILLY H: Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16: 216-20.
43. SATO TA, WIDMER MB, FINKELMAN FD et al.: Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993; 150: 2717-23.
44. FINKELMAN FD, MADDEN KB, MORRIS SC et al.: Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151: 1235-44.
45. BOYMAN O, RAMSEY C, KIM DM, SPRENT J, SURH CD: IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 2008; 180: 7265-75.
46. RUBINSTEIN MP, KOVAR M, PURTON JF et al.: Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 2006; 103: 9166-71.
47. VERDEIL G, MARQUARDT K, SURH CD, SHERMAN LA: Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci USA 2008; 105: 16683-8.